Details

Autor(en) / Beteiligte

• Lancione, Marta
• Donatelli, Graziella
• Del Prete, Eleonora
• Campese, Nicole
• Frosini, Daniela
• Cencini, Matteo
• Costagli, Mauro
• Biagi, Laura
• Lucchi, Giacomo
• Tosetti, Michela
• Godani, Massimiliano
• Arnaldi, Dario
• Terzaghi, Michele
• Provini, Federica
• Pacchetti, Claudio
• Cortelli, Pietro
• Bonanni, Enrica
• Ceravolo, Roberto
• Cosottini, Mirco

Titel

Evaluation of iron overload in nigrosome 1 via quantitative susceptibility mapping as a progression biomarker in prodromal stages of synucleinopathies

Ist Teil von

• NeuroImage (Orlando, Fla.), 2022-10, Vol.260, p.119454-119454, Article 119454

Ort / Verlag

Amsterdam: Elsevier Inc

Erscheinungsjahr

2022

Link zum Volltext

Quelle

Elsevier ScienceDirect Journals Complete

Beschreibungen/Notizen

• •We evaluated iron deposition in N1 in HC and patients with early PD (ePD) and iRBD.•N1 aspect was pathological in T2*-w images in 45% of iRBD patients and in most ePD.•ePD N1 χ was higher than iRBD and HC χ but had no correlation with disease duration.•N1 χ in iRBD was similar to HC but increased with disease duration.•N1 χ may be a presymptomatic biomarker for neurodegeneration in prodromal PD. Idiopathic rapid eye movement (REM) sleep behavior disorder (iRBD) is a prodromal stage of α-synucleinopathies, such as Parkinson's disease (PD), which are characterized by the loss of dopaminergic neurons in substantia nigra, associated with abnormal iron load. The assessment of presymptomatic biomarkers predicting the onset of neurodegenerative disorders is critical for monitoring early signs, screening patients for neuroprotective clinical trials and understanding the causal relationship between iron accumulation processes and disease development. Here, we used Quantitative Susceptibility Mapping (QSM) and 7T MRI to quantify iron deposition in Nigrosome 1 (N1) in early PD (ePD) patients, iRBD patients and healthy controls and investigated group differences and correlation with disease progression. We evaluated the radiological appearance of N1 and analyzed its iron content in 35 ePD, 30 iRBD patients and 14 healthy controls via T2*-weighted sequences and susceptibility (χ) maps. N1 regions of interest (ROIs) were manually drawn on control subjects and warped onto a study-specific template to obtain probabilistic N1 ROIs. For each subject the N1 with the highest mean χ was considered for statistical analysis. The appearance of N1 was rated pathological in 45% of iRBD patients. ePD patients showed increased N1 χ compared to iRBD patients and HC but no correlation with disease duration, indicating that iron load remains stable during the early stages of disease progression. Although no difference was reported in iron content between iRBD and HC, N1 χ in the iRBD group increases as the disease evolves. QSM can reveal temporal changes in N1 iron content and its quantification may represent a valuable presymptomatic biomarker to assess neurodegeneration in the prodromal stages of PD. [Display omitted] .